Literature DB >> 7733636

The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake.

L D Skarsgard1, M W Skwarchuk, A Vinczan, J Kristl, D J Chaplin.   

Abstract

In the present in vitro studies we examined the effect of hypoxia and acidic pH, two important consequences of reduced blood flow in vivo, on the cytotoxicity of melphalan treatment in Chinese hamster V79-WNRE and SiHa human tumor cells. Cells were exposed to various concentrations of melphalan for 1 hr at 37 degrees C under oxic or hypoxic conditions; pH 6.6 or 7.4, and cell survival was measured. The cytotoxicity of melphalan was potentiated by both low pH and hypoxia, in both cell lines. The overall potentiation, expressed as an enhancement ratio (ER), from both hypoxia and low pH was 3.5 in V79-WNRE and 2.9 in SiHa cells. The potentiation of cell killing produced by hypoxia alone (ERHyp) ranged from 1.4 to 1.9, and was greater in V79-WNRE than in SiHa cells. The potentiation from low pH (ERpH) was approximately 2 in both cell lines. HPLC analysis showed substantial intracellular accumulation of melphalan in both cell lines. Hypoxia and reduced pH further enhanced uptake of melphalan but this was not sufficient by itself to account for the increased potentiation of cytotoxicity observed under those conditions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7733636

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

Review 1.  Clinical pharmacology in the adolescent oncology patient.

Authors:  Gareth J Veal; Christine M Hartford; Clinton F Stewart
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 2.  Drug resistance and cellular adaptation to tumor acidic pH microenvironment.

Authors:  Jonathan W Wojtkowiak; Daniel Verduzco; Karla J Schramm; Robert J Gillies
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

3.  Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Rong Zhou; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2015-03       Impact factor: 4.044

4.  A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.

Authors:  Georgia M Beasley; Ketan Sharma; Joyce Wong; Mike Miller; Ryan S Turley; Michael Lidsky; Melanie Masoud; Mark W Dewhirst; Paul J Mosca; Jonathan S Zager; Douglas S Tyler
Journal:  Cancer       Date:  2012-06-06       Impact factor: 6.860

Review 5.  Isolated limb infusion as a model to test new agents to treat metastatic melanoma.

Authors:  Michael E Lidsky; Paul J Speicher; Betty Jiang; Masahito Tsutsui; Douglas S Tyler
Journal:  J Surg Oncol       Date:  2013-11-20       Impact factor: 3.454

Review 6.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

7.  (31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Authors:  Kavindra Nath; David S Nelson; Andrew M Ho; Seung-Cheol Lee; Moses M Darpolor; Stephen Pickup; Rong Zhou; Daniel F Heitjan; Dennis B Leeper; Jerry D Glickson
Journal:  NMR Biomed       Date:  2012-06-29       Impact factor: 4.044

8.  An isolated limb infusion technique: a guide for the perfusionist.

Authors:  Patricia McDermott; D Scott Lawson; Richard Walczak; Douglas Tyler; Ian R Shearer
Journal:  J Extra Corpor Technol       Date:  2005-12

9.  Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma.

Authors:  Betty S Jiang; Georgia M Beasley; Paul J Speicher; Paul J Mosca; Michael A Morse; Brent Hanks; April Salama; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2014-04-04       Impact factor: 5.344

Review 10.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.